- Previous Close
3.1000 - Open
3.1800 - Bid 3.1800 x --
- Ask 3.2600 x --
- Day's Range
3.1800 - 3.1800 - 52 Week Range
3.1000 - 12.2000 - Volume
459 - Avg. Volume
7 - Market Cap (intraday)
212.722M - Beta (5Y Monthly) 0.71
- PE Ratio (TTM)
-- - EPS (TTM)
-1.1200 - Earnings Date Mar 12, 2025 - Mar 17, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.
www.larimartx.comRecent News: ZA71.F
View MorePerformance Overview: ZA71.F
Trailing total returns as of 1/20/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ZA71.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ZA71.F
View MoreValuation Measures
Market Cap
206.88M
Enterprise Value
14.34M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.03
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-28.55%
Return on Equity (ttm)
-44.50%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-64.77M
Diluted EPS (ttm)
-1.1200
Balance Sheet and Cash Flow
Total Cash (mrq)
203.71M
Total Debt/Equity (mrq)
2.70%
Levered Free Cash Flow (ttm)
-35.22M